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Abstract	
Background	Women	with	contralateral	breast	cancer	(CBC)	have	significantly	worse	prognosis	compared	to	women	with	unilateral	cancer.	A	possible	explanation	of	the	poor	prognosis	of	patients	with	CBC	is	that	in	a	subset	of	patients,	the	second	cancer	is	
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not	a	new	primary	tumor,	but	a	metastasis	of	the	first	cancer	that	has	potentially	obtained	aggressive	characteristics	through	selection	of	treatment.	Exome	and	whole-genome	sequencing	of	solid	tumors	has	previously	been	used	to	investigate	the	clonal	relationship	between	primary	tumors	and	metastases	in	several	diseases.		
Patients	and	methods	In	order	to	assess	the	relationship	between	the	first	and	the	second	cancer,	we	performed	exome	sequencing	to	identify	somatic	mutations	in	both	first	and	second	cancers	compared	paired	normal	tissue	of	25	patients	with	metachronous	CBC.		
Results	For	three	patients,	we	identified	shared	somatic	mutations	indicating	a	common	clonal	origin	thereby	demonstrating	that	the	second	tumor	is	a	metastasis	of	the	first	cancer,	rather	than	a	new	primary	cancer.	Accordingly,	these	patients	all	developed	distant	metastasis	within	3	years	of	the	second	diagnosis,	compared	with	7	out	of	22	patients	with	non-shared	somatic	profiles.		
Conclusions	Genomic	profiling	of	both	tumors	help	the	clinicians	distinguish	between	true	contralateral	breast	cancers	and	subsequent	metastases.		
Keywords	Breast	cancer,	Contralateral,	Bilateral,	recurrence,	metastasis		 	
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Introduction	Breast	cancer	is	one	of	the	world’s	most	common	forms	of	cancer,	accounting	for	approximately	1.4	million	new	cases	annually	worldwide[1].	Women	with	breast	cancer	have,	20	years	after	their	initial	diagnosis,	10-15%	cumulative	incidence	of	second	primary	breast	cancer	in	the	opposite	breast;	contralateral	breast	cancer	(CBC)	[4,5].	We	and	others	have	previously	shown	that	women	with	CBC	have	significantly	worse	prognosis	compared	to	women	with	unilateral	cancer[2,	3].		It	is	likely	that	for	a	subset	of	the	patients,	the	second	cancer	is	not	a	new	primary	tumor,	but	instead	a	metastasis	of	the	first	cancer,	which	could,	in	part,	explain	the	poor	prognosis	of	these	patients.		Several	earlier	attempts	have	been	made	to	use	molecular	methods	to	investigate	this	hypothesis;	Janschek	et	al.	compared	mutations	in	the	p53-gene[4],	Imyaitov	et	al.	investigated	the	allelic	imbalance	profiles[5]	and	Brommesson	et	al.	and	Teixeira	et	al.	used	comparative	genomic	hybridization[6,	7].		Exome	sequencing	has	proved	useful	to	identify	somatic	mutations	and	investigate	the	clonal	relationship	between	primary	tumors	and	various	forms	of	recurrences	in	a	wide	range	of	cancers,	including	breast	cancer[8-11].	Taken	together,	the	results	from	exome	sequencing	in	the	field	of	oncology	show	a	large	genetic	diversity	between	tumors	from	different	patients,	with	only	few	positions	in	the	genome	being	mutated	in	10%	or	more	of	cancer	cases.	When	combined,	mutations	across	patients	show	a	limited	set	of	gene	categories	that	have	oncogenic	or	tumor	suppressive	capacity.	However,	exome	sequencing	it	has	not	previously	been	applied	to	the	case	of	contralateral	breast	cancer.		The	aim	of	this	study	was	to	use	exome	sequencing	to	determine	whether	the	second	tumor	was	a	metastasis	of	the	first.	As	the	treatment	and	prognosis	for	patients	with	CBC	differs	from	that	of	patients	with	metastatic	breast	cancer,	a	technique	for	determining	the	origin	of	the	second	cancer	would	be	of	great	clinical	importance.		
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Methods	
Study	population	
	From	the	Stockholm	Breast	Cancer	Registry,	we	identified	women	who	were	diagnosed	with	primary	breast	cancer	with	a	time	between	the	two	diagnoses	of	6	months	to	5	years.	Based	on	availability	of	archived	material,	we	selected	a	subset	of	25	patients	for	whom	we	collected	formalin	fixed	paraffin	embedded	tissue	(FFPE)	(total	50	tumors),	medical	record	information	(on	adjuvant	treatment	for	the	two	cancers	and	ER-status)	and	follow-up	information	from	Stockholm	Breast	Cancer	Register	(date	of	distant	metastasis	and	date	of	death).	Clinical	characteristics	of	the	selected	patients	are	available	in	Table	1.			
Tissue	collection	and	Laser	Microdissection	In	order	to	identify	somatic	variants	from	private	or	uncommon	germline	variants,	a	paired	normal	(non-cancerous)	sample	is	required	for	each	patient.	FFPE	tissue	for	these	tumors	was	collected,	sectioned	and	stained	with	haematoxylin	and	eosin	(HE)	and	reviewed	by	a	pathologist	to	identify	cancer	cells	and	distinguish	them	from	non-cancerous	cells.	In	order	to	increase	the	tumor	cell	content	of	the	tumor	samples	as	well	as	to	get	a	normal	germline	control	for	downstream	sequencing,	we	performed	laser	microdissection	on	HE-stained	20-µm	sections.	Areas	of	tissue	containing	non-cancerous	tissue	but	a	high	fraction	of	nucleated	cells	were	sorted	to	one	tube,	and	cancerous	tissue	was	sorted	to	a	separate	tube.		
DNA	extractions,	library	preparation	and	sequence	capture	DNA	was	extracted	from	the	microdissected	tissue	using	QiaAmp	DNA	Micro	(QiaGen)	as	instructed	by	the	manufacturer.	Quantification	of	the	total	amount	of	extracted	DNA	was	performed	using	Qubit	DS	DNA	HS	kit	(Life	Technologies).	Sequencing	libraries	were	prepared	by	tagmentation	using	Nextera	DNA	Sample	Prep	Kit	(Epicentre)	using	the	HMW	buffer	and	barcode	option	as	instructed	by	the	manufacturer.	Libraries	were	quantified	using	Qubit	(as	above),	pooled	in	equimolar	amounts	and	subjected	to	exome	capture	using	EZ	Exome	version	1.0	(Nimblegen)	
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using	blocking	adapters	designed	to	match	the	Nextera	library	constructs	otherwise	performed	as	instructed	by	the	manufacturer.	Libraries	were	diluted	for	sequencing	on	HiSeq2000	(Illumina)	with	the	addition	of	Nextera-specific	sequencing	primers	as	instructed	by	Epicentre.			
Raw	sequence	data	processing	and	somatic	variant	calling	Raw	paired-end	reads	were	adapter-trimmed	and	merged	with	SeqPrep	[12]	with	a	maximum	merged	base	quality	of	50	and	adapter	sequences	CTGTCTCTTATACA	and	CTGTCTCTTATACA	(-A	and	-B	flags,	respectively).	Merged	reads	and	unmerged	pairs	were	aligned	to	the	human	reference	genome	GRCh37	using	bwa	v0.6.2[13]	and	sorted	and	indexed	with	samtools	v0.1.18[14].	Amplification	duplicates	were	removed	with	Picard	MarkDuplicates	v1.85[15]	after	which	Base	Quality	Score	Recalibration	and	Local	Realignment	was	performed	using	GATK	v2.4.7[16].	Somatic	mutations	in	the	target	intervals	+/-	200	base	pairs	were	identified	using	MuTect	v1.1.4[17].	Any	variant	present	in	dbSNP	v137	was	removed	from	further	analysis.	In	order	to	improve	the	sensitivity	to	detect	shared	variants,	we	used	the	total	set	of	variants	detected	in	tumors	1	and	2	for	each	patient,	and	calculated	the	allele	fraction	of	these	variants	in	both	tumors.	This	methodology	help	detecting	variants	with	low	allele	fraction,	that	are	present	in	both	tumors	but	might	otherwise	be	detected	in	only	one	of	the	tumors.	Somatic	mutations	that	have	arisen	early	in	the	development	of	the	first	tumor	(both	those	that	confer	an	increase	in	proliferation;	driver	mutations,		and	those	that	do	not;	passenger	mutations)	will	be	present	in	most	or	all	tumor	cells	of	that	tumor.	If	a	cell	from	the	first	tumor	seeds	a	metastasis,	the	mutations	present	in	that	cell	(both	passengers	and	drivers)	will	be	present	in	all	subsequent	tumor	cells	of	the	metastasis.	Therefore	we	only	used	clonal	mutations	to	infer	relatedness.	In	practice,	this	was	accomplished	by	only	retaining	the	top	25%	with	highest	allele	fraction.	If	a	patient’s	tumors	shared	two	or	more	somatic	mutations	at	this	high	fraction,	they	were	considered	to	be	of	common	clonal	origin.	
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Ethics	statement	The	study	was	approved	by	the	Regional	Ethical	Review	Board	in	Stockholm	with	registration	numbers	2005/1288	-31/1	and	2006/362-32.	The	study	did	not	require	written	consent	from	the	participating	individuals.		
Results	The	patients	we	selected	represent	a	diverse	set	of	breast	cancer	patients	in	relation	to	age	of	onset,	treatment	and	histopathological	parameters	(Table	1).	Across	the	50	tumors	and	paired	normal	samples	in	this	study,	we	sequenced	2385583114	reads	yielding	a	mean	target	coverage	of	22.3x	per	sample.	In	total,	we	called	3308	somatic	mutations,	with	a	median	of	52	mutations	per	tumor	that	passed	the	default	quality	filters	of	MuTect.	No	somatic	mutations	were	shared	between	patients,	similar	to	previous	studies	on	breast	cancer	exome	sequencing[18].		We	identified	three	patients	where	the	somatic	mutations	were	shared	between	the	first	and	the	second	cancers,	indicative	of	metastatic	spread	rather	than	a	second	primary	tumor.	Notable,	these	three	patients	we’re	all	diagnosed	at	a	relatively	young	age	(39,	42	and	51,	mean	age	of	cohort	was	54)	and	all	had	ER-negative	first	tumors,	as	well	as	second	tumors	(ER	status	is	missing	for	the	second	tumor	of	patient	354).	In	Figure	1,	examples	of	a	patient	with	a	shared	profile	(patient	177,	a)	and	a	patient	with	a	non-shared	profile	(patient	806,	b)	are	shown.	For	patient	177,	shared	mutations	are	present	at	high	fraction	in	both	tumors,	whereas	no	mutations	with	a	high	allelic	fraction	are	found	for	patient	806.		
Prognosis	We	followed	the	outcome	of	the	patients,	recording	metastasis	and	death,	until	Dec	31	2012.	All	three	patients	predicted	to	have	metastatic	disease	were	clinically	diagnosed	with	metastatic	disease	within	three	years	of	their	second	diagnosis	(Figure	2).	In	contrast,	among	the	22	patients	with	no	shared	mutations	between	the	tumors,	7	developed	distant	metastasis	within	a	three-year	period,	whereas	15	did	not	develop	distant	metastasis	or	did	so	more	than	three	years	from	their	second	breast	cancer	diagnosis	(3	of	3	vs.	7	of	22,	one-tailed	Fisher’s	exact	test	p=0.05).		
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Discussion	In	this	study,	we	show	that	3	of	25	CBC-patients	have	a	shared	mutation	pattern	between	the	first	and	the	second	tumor,	indicating	that	the	second	cancer	is	likely	to	be	a	metastasis	of	the	first.	We	also	find	this	shared	pattern	to	correlate	with	an	increased	risk	for	clinical	diagnosis	of	distant	metastasis	within	a	three-year	period.	Other	studies	have	previously	investigated	the	relationship	between	the	first	and	second	cancer,	using	various	methodologies.	Banelli	and	colleagues	investigated	the	methylation	patterns	of	the	androgen	receptor	in	19	patients	with	contralateral	breast	cancer,	with	successful	assay	data	for	only	10	patients[19].	In	none	of	the	10	patients,	the	second	tumor	was	determined	to	be	a	recurrence	of	the	first.	Janschek	
et	al.	investigated	TP53	mutations	across	33	patients,	but	were	due	to	the	single-gene	assay	and	lack	of	normal	tissue,	only	able	to	determine	the	clonal	status	for	13	patients,	of	which	two	were	determined	to	have	a	metastasis	rather	than	a	second	primary.	Imyanitov	et	al.	determined	status	for	all	but	one	of	28	investigated	cases,	using	14	fixed	markers	for	each	tumor[5],		showing	a	higher	similarity	between	synchronous	CBC	than	metachronous	CBC.	Two	studies	have	used	CGH	to	investigate	the	relationship	between	the	tumors,	showing	that	investigation	of	genomic	imbalances	can	be	used	to	detect	recurrent	breast	tumors	in	both	the	ipsilateral	and	contralateral	settings[6,	7].	In	each	study,	a	single	patient	was	detected	to	have	a	metastasis	instead	of	a	second	primary,	out	of	8	bilateral	cases	in	the	Brommesson	et	al.	study,	and	9	bilateral	cases	in	the	Teixeira	et	al.	study.		In	our	study,	we	used	exome	sequencing	to	identify	if	two	tumors	carry	shared	mutations	at	high	mutational	fractions	as	a	proxy	for	a	common	origin.	The	benefits	of	using	somatic	mutations	is	two-fold:	1)	Mutations	are	not	dynamic	in	nature.	A	mutation	can	be	lost	if	a	segment	of	a	chromosome	is	deleted,	but	this	will	affect	only	a	minority	of	the	mutations.	2)	The	majority	of	mutations	identified	in	the	exome	are	random	passenger	mutations,	under	little	or	no	selective	pressure.	The	resulting	mutational	pattern	is	unique	for	each	tumor,	offering	means	to	identify	common	somatic	denominators	to	metastatic	lesions.	Since	de	novo	mutations	occur	in	every	cell	division,	a	tumor	mass	is	a	mosaic	of	cells	carrying	slightly	different	
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somatic	mutations.	We	used	mutations	with	high	mutational	frequency	since	those	mutations	arose	early	in	the	development	of	the	tumor	and	therefore	have	a	high	likelihood	of	being	present	in	any	cells	originating	from	the	primary	tumor.	The	same	passenger	mutations	are	not	expected	to	occur	in	an	independent	second	primary	tumor.	If	common	mutations	would	be	found,	it	would	strongly	indicate	a	common	somatic	origin.		Two	limitations	have	to	be	acknowledged	in	our	study.	Firstly,	we	used	FFPE	tumors,	the	oldest	of	which	were	resected	in	the	late	1970s.	Since	no	paired	blood	samples	were	available,	we	performed	laser	capture	microscopy	to	obtain	pure	populations	of	tumor	and	normal	cells.	Working	with	very	small	amounts	of	DNA	extracted	from	FFPE	material	limits	both	the	quality	of	the	sequencing	data,	as	well	as	the	amount	of	data	obtained,	as	indicated	by	a	relatively	low	average	coverage	in	our	data.		Clinical	sequencing	of	cancer	holds	great	promise	to	improve	the	treatment	of	cancer.	Molecular	subtyping	and	grading	in	breast	cancer	has	been	shown	to	improve	upon	the	standard	immunohistochemical	and	histopathological	analyses[20,	21]	and	with	the	advent	of	Next	Generation	Sequencing,	molecular	pathology	is	rapidly	advancing.	We	show	that	investigation	of	the	somatic	mutation	patterns	aids	in	identifying	patients	with	metastatic	disease	over	patients	with	a	new	primary	cancer.	In	a	clinical	setting,	the	limitations	of	our	study	will	not	be	applicable.	Access	to	a	blood	sample,	a	skin	punch,	or	unaffected	lymph	nodes	means	that	no	laser	microdissection	needs	to	be	performed,	thereby	simplifying	the	laboratory	procedure.	Thus,	downstream	molecular	methods	can	then	be	carried	out	with	greatly	increased	amounts	of	input	DNA,	increasing	both	the	throughput	and	the	quality	of	the	acquired	data.		
Conclusions	The	treatment	regimens	for	breast	cancer	are	very	different	in	the	primary	setting	and	the	metastatic	setting.	Therefore,	being	able	to	determine	whether	a	tumor	is	a	new	primary	or	a	recurrence	of	a	previous	cancer	is	of	utmost	importance.	In	addition,	as	our	knowledge	on	genomic	patterns	associated	with	treatment	
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resistance	increases,	genomic	profiling	will	be	able	to	provide	a	more	direct	guidance	on	what	treatment	to	select.	As	sequencing	steps	in	to	the	clinical	routine	analysis	of	cancer	and	their	recurrences,	this	will	be	an	important	part	in	directing	the	right	treatment	to	the	right	patient,	and	thereby	improve	survival.		
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Figure	Legends	
Figure	1	Figure	1.	Allele	frequencies	for	two	example	cases.	(A)	Several	somatic	mutations	present	at	high	mutational	fraction	in	both	tumors,	indicating	that	tumor	2	was	formed	by	a	clonal	expansion	of	cells	from	tumor	1.	(B)	No	somatic	mutations	shared	between	tumor	1	and	2,	indicating	that	the	two	tumors	are	independent	events.	Plots	for	all	patients	are	available	in	the	Additional	File	1.	
Figure	2	Figure	2.	Time	from	second	diagnosis	and	potential	diagnosis	of	distant	metastasis.	For	three	patients	(168,	177	and	354,	blue	and	marked	with	asterisk)	we	predict	that	the	second	tumor	is	not	an	independent	tumor,	but	a	clonal	expansion	(metastasis)	of	the	first.	These	three	patients	were	all	diagnosed	with	distant	metastasis	within	three	years	after	their	second	breast	cancer	diagnosis.	Death	or	end	of	follow-up	is	indicated	by	solid	or	open	squares,	respectively.		
Tables	
Table	1	Table	1.	Characteristics,	treatment	and	estrogen	receptor	status	of	the	patients	included	in	the	study.	RT,	radiotherapy;	HT,	hormone	therapy;	CT,	chemotherapy.		
Patient
Year of 
first 
cancer
Age at 
first 
cancer
Time between 
cancers (years)
Time from 
second cancer 
to metastasis 
(years)
Treatment for 
first cancer
Treatment for 
second cancer
ER-status at 
first cancer
ER-status at 
second cancer
779 1990 62 2,08 RT+HT HT Positive Negative
351 2000 48 4,07 RT+HT RT+HT Positive Positive
941 1997 63 1,03 CT HT Negative Positive
683 2002 77 1,86 NT HT Negative Positive
621 1985 62 1,79 2,15 RT NT Positive Positive
354 * 1992 39 3,39 0,28 RT+CT+HT HT Negative Unknown
177 * 1983 42 1,42 2,30 RT RT+CT Negative Negative
409 1999 37 2,47 RT+CT+HT RT+CT+HT Positive Negative
886 2003 71 1,53 1,40 RT HT Negative Positive
168 * 1994 51 2,91 2,59 RT+CT RT+CT+HT Negative Negative
806 2000 71 4,41 HT HT Positive Positive
169 1987 51 1,28 3,13 RT+CT HT Negative Positive
742 1989 62 4,50 7,99 NT NT Positive Unknown
3029 2001 51 4,78 RT+CT+HT CT Positive Negative
209 1991 46 4,21 HT NT Negative Positive
198 1999 55 4,85 RT+CT+HT CT Positive Negative
126 2000 58 4,74 RT RT+HT Positive Positive
3030 1996 45 0,41 3,51 NT RT+CT Negative Negative
639 1985 61 3,53 HT NT Negative Negative
340 2001 50 3,13 RT+CT RT+HT Negative Positive
919 1998 65 4,59 RT+CT RT+HT Negative Positive
30276 1981 74 4,90 1,74 RT+HT HT Positive Negative
383 1987 31 0,65 RT RT+CT Positive Positive
275 1990 43 3,91 NT CT+HT Positive Positive
404 1998 39 2,68 2,40 CT+HT RT+CT+HT Positive Negative
Mean 54,16 3,01 2,75
